Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Novavax Inc (NVAX) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Novavax Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $21.89, while Novavax Inc trades at $8.42 (market cap $1.38B). The key difference: Novavax Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

BOILNVAX
Sector
Leveraged / InverseHealth
52-Week High
$98.62$11.19
52-Week Low
$21.86$6.22
Market Cap
$1.38B
Enterprise Value
$889.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.

The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX